Markus F. Herzig

Keine laufenden Positionen mehr

78 Jahre

Health Technology

Profil

Markus F.
Herzig has been Vice President of Regulatory Affairs for Allos Therapeutics, Inc. since August 2001.
Previously, he was Executive Director of Regulatory Affairs and Quality Assurance for OraPharma, Inc. from January 1999 to August 2001.
From January 1986 to December 1998, Mr. Herzig held management positions at Takeda Pharmaceuticals America, Inc., Novo Nordisk Pharmaceuticals, Inc., Organon, Inc. and Sandoz Pharmaceuticals Corp.
He received an MS degree from Allgemeine Gewerbe Schule in Basel, Switzerland.

Ehemalige bekannte Positionen von Markus F. Herzig

Unternehmen	Position	Ende
Allos Therapeutics, Inc. Allos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Allos Therapeutics, Inc. is a biopharmaceutical company committed to the development and commercialization of innovative anti-cancer therapeutics. It focuses on the development and commercialization FOLOTYN a pralatrexate injection. FOLOTYN is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells. It targets the inhibition of dihydrofolate reductase, or DHFR, an enzyme critical in the folate pathway, thereby interfering with DNA and RNA synthesis and triggering cancer cell death. Allos Therapeutics is also developing FOLOTYN in other hematologic malignancies and solid tumors. The company was founded on September 1, 1992 and is headquartered in Westminster, CO.	General Counsel	-

Sehen Sie sich die Erfahrung von Markus F. Herzig im Detail an

Erfahrungen
Besetzte Positionen

Aktive

Inaktive

Börsennotierte Unternehmen

Private Unternehmen